Trials / Recruiting
RecruitingNCT07175285
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 223 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Current standard of care treatment options | According to the product label |
Timeline
- Start date
- 2025-10-08
- Primary completion
- 2028-03-01
- Completion
- 2032-11-01
- First posted
- 2025-09-16
- Last updated
- 2026-04-13
Locations
53 sites across 12 countries: United States, Argentina, Brazil, Canada, France, Germany, Israel, Italy, Japan, Puerto Rico, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07175285. Inclusion in this directory is not an endorsement.